Clinical Trials

  • Principal Investigator:

    Jennifer M. Bain, MD, PhD
    Neurodevelopmental disorders are a group of disorders in which the development of the central nervous system is disturbed. The genetic basis for many neurodevelopmental disorders has continued to expand, and a recent gene called HNRNPH2 (Heterogeneous Nuclear Ribonucleoprotein H2, encoded by HNRNPH2) is one such gene that is associated with a common neurodevelopmental disorder, characterized by developmental delay, intellectual disability, autism and autistic features, and tone abnormalities among other multisystem problems (Bain et al., 2016). The investigators have expanded the genetic...
  • Principal Investigator:

    Andrew B. Lassman, MD
    The purpose of this study is to measure how well and how safe eflornithine is in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has come back after radiation and chemotherapy. Safety and how well you can tolerate the drug will be determined on the basis of physical exams, laboratory tests, and questions about any problems you might experience during the study.
  • Principal Investigator:

    Andrew B. Lassman, MD
    The purpose of this research study is to see if the combination of medications approved for the treatment of glioblastoma, together with the study drug, selinexor (also known as XPOVIO), has any effects on your cancer. Selinexor works by trapping tumor suppressor proteins within the cell nucleus. This is expected to cause the cancer cells to die or stop growing. Selinexor is approved by the U.S. Food and Drug Administration (FDA) for the use in certain patients with multiple myeloma but has not yet been approved by the FDA for the treatment of your type of cancer.
  • Principal Investigator:

    Richard P. Mayeux, MD, MSc
    This study seeks to identify genes increasing the risk of Alzheimer's disease. The National Institute on Aging-Late Onset Alzheimer's Disease Family Study (NIA-LOAD Family study) is a nationwide research study to find the genes that play a role in Alzheimer's disease (AD), and to learn more about the causes of AD, and how to treat or prevent it. We are currently enrolling families with two or more members with Alzheimer's disease or memory problems. Family members can can live anywhere in the U.S. Enrolled participants will undergo cognitive testing and a blood draw in their home, and will be...
  • Principal Investigator:

    Andrew B. Lassman, MD
    The purpose of this study is to evaluate multiple investigational treatments for either newly diagnosed or recurrent brain tumors to determine if any of these study treatment(s) improve overall survival as compared to standard treatments. Investigational means that these are new treatments sometimes called study drugs and are not approved by the Food and Drug Administration (FDA) to be used for your type of cancer. The investigational treatments in this study have been previously tested in people.
  • Principal Investigator:

    Matthew B. Harms, MD
    This program provides family members of individuals with familial ALS the opportunity to contribute to research focused on learning more about why motor neuron degeneration begins and how or why it progresses. This study provides genetic counseling and testing to help participants understand and manage their risk and determine if they want to learn their genetic status. This study will follow unaffected ALS gene mutation carriers on an annual basis to gather essential information that will ultimately help researchers develop novel therapies for the prevention and treatment of ALS. The ALS...
  • Principal Investigator:

    Scott A. Small, MD
    For more than 30 years, The Columbia University Alzheimer's Disease Research Center (ADRC) has worked with thousands of participants who have helped provide important insights into how the brain ages and why Alzheimer's disease may develop. We are actively recruiting adults 65 years of age and older who share our commitment to be part of this nationwide study. Younger participants are welcome if there is a personal or family history of memory loss. Participants, both with and without memory problems, will be comprehensively evaluated beginning with a physician taking a history and performing...
  • Principal Investigator:

    Scott A. Small, MD
    For more than 30 years, The Columbia University Alzheimer's Disease Research Center (ADRC) has worked with thousands of participants who have helped provide important insights into how the brain ages and why Alzheimer's disease may develop. We are actively recruiting adults 65 years of age and older who share our commitment to be part of this nationwide study. Younger participants are welcome if there is a personal or family history of memory loss. Participants, both with and without memory problems, will be comprehensively evaluated beginning with a physician taking a history and performing...
  • Principal Investigator:

    Victoria M. Leavitt
    ASPIRE is a clinical trial to investigate aspirin as a treatment to improve exercise performance in people with multiple sclerosis (MS) who experience overheating during exercise. Persons with multiple sclerosis benefit from exercise, but many avoid it because of exhaustion and overheating. This randomized controlled trial (RCT) tests aspirin as a method to increase time to exhaustion for persons with MS, through its antipyretic mechanism. Participants will be seen at our laboratory for maximal exercise tests on three separate days. At each session, they will be given one of three treatments...
  • Principal Investigator:

    Edward Denmead Huey, MD
    The purpose of this study is to carefully examine how dementia can affect mood and behavior. In this study, we will use Magnetic Resonance Imaging (MRI) to better understand the relationship between thinking, mood, behavior and the brain. We are currently seeking participants who have a diagnosis of dementia, such as Alzheimer's Disease, who are between 40-90 years old, and who speak English or Spanish. Participation involves coming in with a study partner (someone who knows you well) for a single visit for a total of 4-5 hours. Participants will answer questions about their recent mood and...

Pages